Cellectar Biosciences, Inc. Resources

Patients News & Media Investors Contact

Cellectar Biosciences, Inc.

  • Home
  • About
    • Overview
    • Partnerships
    • Management Team
    • Board of Directors
  • Platform
    • Overview
    • Posters & Publications
  • Product Pipeline
    • Overview
    • Iopofosine
  • Clinical Studies
    • Overview
    • Waldenstrom’s Macroglobulinemia Phase 2 Study Active, not recruiting
    • Relapsed or Refractory Select B-Cell Malignancies Clinical Study Active, not recruiting
    • Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG Active, not recruiting
  • Patients
  • News & Media
  • Investors
  • Contact

Press Releases

News & Media

News & Media

  • Press Releases
  • Presentations
  • Events

Cellectar Biosciences Announces Key Commercial Team Appointments

Apr 12, 2022

Cellectar Reports Financial Results for Year Ended December 2021 and Provides a Corporate Update

Mar 21, 2022

Cellectar to Participate at Upcoming Banking Conferences

Mar 10, 2022

Cellectar Biosciences Announces Executive Leadership Changes

Feb 23, 2022

Cellectar to Participate in Fireside Chat at the H.C. Wainwright Bioconnect Conference

Jan 4, 2022

Cellectar Presented Data from its Ongoing Phase 2 CLOVER-1 Study of Iopofosine I-131 at the 63rd ASH Annual Meeting and Exposition

Dec 13, 2021

Cellectar Biosciences Announces Poster Presentation at the 63rd American Society for Hematology Annual Meeting and Exposition

Dec 8, 2021

Cellectar’s Iopofosine I-131 Exhibits Signals of Efficacy in Phase I Study for Pediatric Brain and Solid Tumors

Nov 16, 2021

Cellectar Reports Financial Results for the Third Quarter 2021 and Provides a Corporate Update

Nov 8, 2021

Cellectar Appoints Laurence Reilly, M.D., LL.M Interim Chief Medical Officer

Nov 2, 2021
    • 1...
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • 13
    • ...37
    © 2025 Cellectar Biosciences, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap Q&A